Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSe basket trial

被引：0
|
作者：
Tomasini, P. [1 ]
Mazieres, J. [2 ]
Cropet, C. [3 ]
Troussard, X. G. [4 ]
Malka, D.
Ray-Coquard, I. L. [5 ,6 ]
Leboulleux, S. [7 ]
Flechon, A. [8 ]
Arnulf, B. [9 ]
Cancel, M. [10 ]
Bieche, I. [11 ]
Collot, S. [12 ]
Taieb, S. [13 ]
Garcia, G. [14 ]
Mandache, A-M. [15 ]
Colignon, N. [16 ]
Gavrel, M. [14 ]
Jimenez, M. [17 ]
Hoog-Labouret, N. [18 ]
Blay, J-Y. [6 ]
机构：
[1] Aix Marseille Univ, AP HM, Dept Multidisciplinary Oncol & Therapeut Innovat, Marseille, France
[2] Toulouse Univ Hosp, Thorac Oncol Dept, Toulouse, France
[3] Ctr Leon Berard, Direct Rech Clin & Innovat DRCI, Lyon, France
[4] CHU Caen Normandie, Hematol, Caen, France
[5] Gustave Roussy, Digest Oncol Dept, Villejuif, France
[6] Ctr Leon Berard, Med Oncol, Lyon, France
[7] Gustave Roussy, Med Nucl & Endocrine Oncol, Villejuif, France
[8] Ctr Leon Berard, Dept Urol Oncol, Lyon, France
[9] Hosp St Louis, APHP, Hematol, Paris, France
[10] CHU Bretonneau, Med Oncol, Tours, France
[11] Paris Descartes Univ, Dept Genet, Inst Curie, Paris, France
[12] CHU Toulouse, Radiol & Med Imagery, Hop Rangueil Larrey, Toulouse, France
[13] Oscar Lambret, Med Imagery, Lille, France
[14] Gustave Roussy, Med Imagery, Villejuif, France
[15] Ctr Leon Berard, Med Imagery, Lyon, France
[16] Hop St Antoine, APHP, Radiol, Paris, France
[17] UNICANCER, R&D Dept, Paris, France
[18] Natl Canc Inst, Res & Innovat, Boulogne, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
538P
引用
收藏
页码：S470 / S471
页数：2
相关论文
共 50 条
  • [41] Clinical characteristics of patients with non-V600 BRAF mutant melanomas.
    Kim, Dae Won
    Nowroozi, Sasan
    Kim, Kunhwa
    Davies, Michael A.
    Routbort, Mark
    Lazar, Alexander J. F.
    Frankian, Silva
    Siroy, Alan
    Bedikian, Agop Y.
    Papadopoulos, Nicholas E.
    Hwu, Wen-Jen
    Hwu, Patrick
    Woodman, Scott
    Patel, Sapna Pradyuman
    Kim, Kevin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Non-V600 BRAF mutations in advanced malignancies: Prevalence and survival impact
    Kheder, Ed
    Xing, Yan
    Hess, Kenneth R.
    Janku, Filip
    Shaw, Kenna Rael
    Huang, Le
    Patel, Keyur
    Meric-Bernstam, Funda
    Subbiah, Vivek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Non-V600 BRAF Mutated Melanomas Have Immune Microenvironments Primed for Immune Checkpoint Inhibitor Response
    Senosain, M.
    Pabla, S.
    Senosain, M.
    Ko, H.
    Pabla, S.
    Seager, R.
    Van Roey, E.
    Gao, S.
    Strickland, K.
    Previs, R.
    Nesline, M.
    Hastings, S.
    Zhang, S.
    Conroy, J.
    Jensen, T.
    Eisenberg, M.
    Caveney, B.
    Severson, E.
    Ramkissoon, S.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S91 - S91
  • [44] Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers
    Rustgi, Naryan
    Maria, Ann
    Toumbacaris, Nicolas
    Zhao, Huiyong
    Kargus, Katherine
    Bryant, Morgan
    Waksmundzki, Alexandra
    Aricescu, Ilinca
    Lefkowitz, Robert A.
    Li, Bob T.
    Chou, Joanne
    Capanu, Marinela
    de Stanchina, Elisa
    Misale, Sandra
    Shia, Jinru
    Yaeger, Rona
    [J]. ONCOLOGIST, 2024, 29 (01): : 15 - 24
  • [45] Vemurafenib in Melanoma with BRAF V600E Mutation REPLY
    Chapman, Paul B.
    Hauschild, Axel
    McArthur, Grant A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15): : 1450 - 1450
  • [46] Dominant role of receptor tyrosine kinase in the activation of MAPK signaling in BRAF non-V600 mutant cancers
    Ebi, Hiromichi
    Kotani, Hiroshi
    Kitai, Hidenori
    Adachi, Yuta
    Yano, Seiji
    [J]. CANCER RESEARCH, 2017, 77
  • [47] Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers
    Offin, M.
    Pak, T.
    Mondaca, S.
    Montecalvo, J.
    Rekhtman, N.
    Halpenny, D.
    Wu, S.
    Kris, M.
    Paik, P.
    Riely, G.
    Rudin, C.
    Hyman, D.
    Hellmann, M.
    Drilon, A.
    Land, J.
    Buie, L.
    Lito, P.
    Yaeger, R.
    Liu, D.
    Li, B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S455 - S455
  • [48] Exploring the mutational landscape of KRAS and NRAS in tumors with non-V600 BRAF mutations
    Mukonoweshuro, Chantel L.
    Rousselle, Emmanuelle
    Rose, April A.
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [49] BRAF V600 mutations and pathological features in Japanese melanoma patients
    Yamazaki, Naoya
    Tanaka, Ryota
    Tsutsumida, Arata
    Namikawa, Kenjiro
    Eguchi, Hironobu
    Omata, Wataru
    Oashi, Kohei
    Ogawa, Toru
    Hayashi, Amiko
    Nakamura, Noriyuki
    Tsuta, Koji
    [J]. MELANOMA RESEARCH, 2015, 25 (01) : 9 - 14
  • [50] THE COST OF STAGE IV MELANOMA WITH BRAF V600 MUTATIONS IN GREECE
    Carayanni, V
    Gogas, H.
    Bafaloukos, D.
    Boukovinas, I
    Latsou, D.
    Stamuli, E.
    Hatzikou, M.
    [J]. VALUE IN HEALTH, 2020, 23 : S462 - S462
12345